Sabra Healthcare REIT (SBRA)
(Delayed Data from NSDQ)
$16.43 USD
+0.28 (1.70%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $16.42 -0.01 (-0.06%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth C Momentum C VGM
Sabra Healthcare (SBRA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$16.45 | $21.00 | $15.00 | 1.79% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Sabra Healthcare comes to $16.45. The forecasts range from a low of $15.00 to a high of $21.00. The average price target represents an increase of 1.79% from the last closing price of $16.16.
Analyst Price Targets (11)
Broker Rating
Sabra Healthcare currently has an average brokerage recommendation (ABR) of 2.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 2.14 a month ago based on 14 recommendations.
Of the 14 recommendations deriving the current ABR, six are Strong Buy, representing 42.86% of all recommendations. A month ago, Strong Buy represented 42.86%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 8 | 8 | 8 | 8 | 9 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.14 | 2.14 | 2.14 | 2.14 | 2.20 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/14/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/20/2024 | Robert W. Baird & Co. | Wesley Golladay | Hold | Hold |
6/17/2024 | Mizuho SecuritiesUSA | Vikram Malhotra | Strong Buy | Strong Buy |
5/28/2024 | Not Identified | Not Identified | Hold | Hold |
5/21/2024 | Not Identified | Not Identified | Hold | Hold |
5/15/2024 | Scotiabank | Nicholas Yulico | Hold | Hold |
4/5/2024 | Truist Securities | Michael Lewis | Strong Buy | Strong Buy |
3/15/2024 | KeyBanc Capital Markets | Austin Wurschmidt | Hold | Hold |
2/29/2024 | Wedbush Securities | Richard Anderson | Strong Buy | Strong Buy |
1/30/2024 | Wells Fargo Securities | Connor Siversky | Hold | Hold |
12/1/2023 | JMP Securities | Aaron Hecht | Hold | Hold |
10/17/2023 | BMO Capital Markets | John P Kim | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.14 |
ABR (Last week) | 2.14 |
# of Recs in ABR | 14 |
Average Target Price | $16.45 |
LT Growth Rate | 4.60% |
Industry | REIT and Equity Trust - Other |
Industry Rank by ABR | 93 of 253 |
Current Quarter EPS Est: | 0.35 |